How Do We Quantify Continuous Manufacturing Benefits?
Source: Sartorius
In this segment of the Bioprocess Online Live event Biopharma PAT: Gateway To Continuous Manufacturing, Paul Testa, EVP of Supply Chain and Operations at Kyowa Kirin North America and Barrett Fallentine, Director, Process & Product Development at Pharmatech Associates cover the intended, expected, and actual outcomes of continuous manufacturing initiatives in biopharma. They also tackle audience questions on modality-specific benefits of continuous manufacturing, and how much those benefits cross over from one product to the next.
View the full presentation on-demand here.
access the Video!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.
Subscribe to Bioprocess Online
X
Subscribe to Bioprocess Online
Sartorius
This website uses cookies to ensure you get the best experience on our website. Learn more